Sam Agresta

5.2k citations
27 papers · 912 · h-index 15

Impact in

  • Hematology top 2%
    • Acute Myeloid Leukemia Research
  • Genetics top 5%
    • Glioma Diagnosis and Treatment

Papers in

  • Hematology 19
    • Acute Myeloid Leukemia Research 14
    • Multiple Myeloma Research and Treatments 3
  • Cancer Research 12
    • Cancer Genomics and Diagnostics 8
    • Cancer, Hypoxia, and Metabolism 8
Co-authors
Katharine Yen (11 shared papers)Hua Yang (14 shared papers)Camelia Gliser (5 shared papers)Hagop M. Kantarjian (2 shared papers)Courtney D. DiNardo (2 shared papers)Bin Fan (8 shared papers)Marina Konopleva (1 shared paper)Sherry Pierce (1 shared paper)
Journals
Blood (12 papers)Cancer Research (4 papers)Molecular Cancer Therapeutics (2 papers)Journal of Clinical Oncology (1 paper)Investigational New Drugs (1 paper)
Partner nations
United StatesFranceIreland

In The Last Decade

Sam Agresta

27 papers receiving 903 citations

Peers

Sam Agresta
Comparison fields: 5 of 54
  • Hematology 442
  • Genetics 285
  • Cancer Research 315
  • Molecular Biology 474
  • Oncology 121
Replace Ashwin Kishtagari with:
Ashwin Kishtagari United States
Annette Fasan Germany
Zineb Hamilou Canada
Gabriella Sammarelli Italy
Dong‐ming Yao China
Carrie Brownstein United States
Kathy L. McGraw United States
Katherine Waghorn United Kingdom
Camelia Gliser United States
Marie Jarošová Czechia
Sam Agresta relative to Ashwin Kishtagari United States Ashwin Kishtagari's profile →
Citations per field
00.5×5×10×15×21.8×
Ashwin Kishtagari · 1×
Citations per year

Countries citing papers authored by Sam Agresta

Since Specialization
Citations

This map shows the geographic impact of Sam Agresta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sam Agresta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sam Agresta more than expected).

Fields of papers citing papers by Sam Agresta

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sam Agresta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sam Agresta. The network helps show where Sam Agresta may publish in the future.

Co-authors

The 25 scholars most cited alongside Sam Agresta, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Sam Agresta Line = papers co-authored together Sam Agresta links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 27 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML
American Journal of Hematology ·Courtney D. DiNardo, Farhad Ravandi, Sam Agresta, Marina Konopleva, Koichi Takahashi, Tapan M. Kadia, Mark J. Routbort, Keyur P. Patel, Mark Brandt, Sherry Pierce, Guillermo Garcia‐Manero, Jörge E. Cortes, Hagop M. Kantarjian
2015213
2
IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition
Blood ·Andrew Kernytsky, Fang Wang, Erica Hansen, Stefanie S. Schalm, Kimberly Straley, Camelia Gliser, Hua Yang, Jeremy Travins, Stuart Murray, Marion Dorsch, Sam Agresta, David P. Schenkein, Scott A. Biller, Shinsan M. Su, Wei Liu, Katharine Yen
2014128
3
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma
Journal of Clinical Oncology ·William D. Tap, Víctor M. Villalobos, Gregory M. Coté, Howard A. Burris, Filip Jankú, Olivier Mir, M. Beeram, Andrew J. Wagner, Liewen Jiang, Bin Wu, Sung Choe, Katharine Yen, Camelia Gliser, Bin Fan, Sam Agresta, Shuchi S. Pandya, Jonathan C. Trent
2020109
4
Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors
Investigational New Drugs ·Bin Fan, Ingo K. Mellinghoff, Patrick Y. Wen, Maeve A. Lowery, Lipika Goyal, William D. Tap, Shuchi S. Pandya, Erika Manyak, Liewen Jiang, Guowen Liu, Tara Nimkar, Camelia Gliser, M. P. Judge, Sam Agresta, Hua Yang, David L. Dai
201971
5
AG-221, an Oral, Selective, First-in-Class, Potent Inhibitor of the IDH2 Mutant Metabolic Enzyme, Induces Durable Remissions in a Phase I Study in Patients with IDH2 Mutation Positive Advanced Hematologic Malignancies
Blood ·Eytan M. Stein, Jessica K. Altman, Robert H. Collins, Daniel J. DeAngelo, Amir T. Fathi, Ian W. Flinn, Arthur E. Frankel, Ross L. Levine, Bruno C. Medeiros, Manish R. Patel, Daniel A. Pollyea, Gail J. Roboz, Richard M. Stone, Ronan Swords, Martin S. Tallman, Sam Agresta, Bin Fan, Hua Yang, Katharine Yen, Stéphane de Botton
201468
6
Isocitrate Dehydrogenase 1 (IDH1) Mutation in Breast Adenocarcinoma Is Associated With Elevated Levels of Serum and Urine 2-Hydroxyglutarate
The Oncologist ·Amir T. Fathi, Hossein Sadrzadeh, Amy Comander, Michaela J. Higgins, Aditya Bardia, Ashley Perry, Meghan Burke, Regina Silver, Christina R. Matulis, Kimberly Straley, Katharine Yen, Sam Agresta, Hyeryun Kim, David P. Schenkein, Darrell R. Borger
201459
7
Molecular Profiling and Relationship with Clinical Response in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Potent Inhibitor of Mutant IDH1, in Addition to Data from the Completed Dose Escalation Portion of the Phase 1 Study
Blood ·Courtney D. DiNardo, Stéphane de Botton, Daniel A. Pollyea, Eytan M. Stein, Amir T. Fathi, Gail J. Roboz, Robert H. Collins, Ronan Swords, Ian W. Flinn, Jessica K. Altman, Martin S. Tallman, Hagop M. Kantarjian, Adnan Derti, Meredith A. Goldwasser, Malia Prahl, Bin Wu, Katharine Yen, Sam Agresta, Richard M. Stone
201545
8
AG-120, an Oral, Selective, First-in-Class, Potent Inhibitor of Mutant IDH1, Reduces Intracellular 2HG and Induces Cellular Differentiation in TF-1 R132H Cells and Primary Human IDH1 Mutant AML Patient Samples Treated Ex Vivo
Blood ·Erica Hansen, Cyril Quivoron, Kim Straley, René M. Lemieux, Janeta Popovici-Müller, Hossein Sadrzadeh, Amir T. Fathi, Camelia Gliser, Muriel D. David, Véronique Saada, Jean‐Baptiste Micol, Olivier Bernard, Marion Dorsch, Hua Yang, Michael Su, Sam Agresta, Stéphane de Botton, Virginie Penard‐Lacronique, Katharine Yen
201440
9
Phase 1 Single‐ and Multiple‐Ascending‐Dose Randomized Studies of the Safety, Pharmacokinetics, and Pharmacodynamics of AG‐348, a First‐in‐Class Allosteric Activator of Pyruvate Kinase R, in Healthy Volunteers
Clinical Pharmacology in Drug Development ·Hua Yang, Elizabeth Merica, Yue Chen, Marvin B. Cohen, Ronald Goldwater, Penelope A. Kosinski, Charles Kung, Zheng Yuan, Lee Silverman, Meredith A. Goldwasser, Bruce A. Silver, Sam Agresta, Ann Barbier
201839
10
Abstract PL04-05: The first reported results of AG-120, a first-in-class, potent inhibitor of the IDH1 mutant protein, in a Phase I study of patients with advanced IDH1-mutant solid tumors, including gliomas
Molecular Cancer Therapeutics ·Howard Burris, Ingo K. Mellinghoff, Elizabeth A. Maher, Patrick Y. Wen, M. Beeram, Mehdi Touat, Jason E. Faris, Nilofer S. Azad, Timothy F. Cloughesy, Lia Gore, Jonathan C. Trent, Daniel D. Von Hoff, Meredith A. Goldwasser, Bin Fan, Sam Agresta
201526
11
1LBA Clinical safety and activity in a phase I trial of AG-120, a first in class, selective, potent inhibitor of the IDH1-mutant protein, in patients with IDH1 mutant positive advanced hematologic malignancies
European Journal of Cancer ·Daniel A. Pollyea, Stéphane de Botton, Amir T. Fathi, E.M. Stein, Martin S. Tallman, Sam Agresta, Chris Bowden, Bin Fan, Melissa Prah, Hong Seok Yang, Katharine Yen, R. M. Stone
201419
12
AG-221, an Oral, Selective, First-in-Class, Potent IDH2-R140Q Mutant Inhibitor, Induces Differentiation in a Xenotransplant Model
Blood ·Cyril Quivoron, Muriel D. David, Kim Straley, Jeremy Travins, Hyeryun Kim, Yue Chen, Dongwei Zhu, Véronique Saada, Olivia Bawa, Paule Opolon, Mélanie Polrot, Jean‐Baptiste Micol, Christophe Willekens, Olivier Bernard, Hua Yang, Sam Agresta, Stéphane de Botton, Katharine Yen, Virginie Penard‐Lacronique
201417
13
Longitudinal Pharmacokinetic/Pharmacodynamic Profile of AG-120, a Potent Inhibitor of the IDH1 Mutant Protein, in a Phase 1 Study of IDH1-Mutant Advanced Hematologic Malignancies
Blood ·Bin Fan, Kha Le, Erika Manyak, Hua Liu, Malia Prahl, Chris Bowden, Scott A. Biller, Sam Agresta, Hua Yang
201516
14
ACTR-46. AG120, A FIRST-IN-CLASS MUTANT IDH1 INHIBITOR IN PATIENTS WITH RECURRENT OR PROGRESSIVE IDH1 MUTANT GLIOMA: RESULTS FROM THE PHASE 1 GLIOMA EXPANSION COHORTS
Neuro-Oncology ·Ingo K. Mellinghoff, Mehdi Touat, Elizabeth A. Maher, Macarena DeLaFuente, Timothy F. Cloughesy, Matthias Holdhoff, Gregory M. Coté, Howard Burris, Filip Jankú, Raymond Y. Huang, Robert R. Young, Benjamin M. Ellingson, Julia Auer, Hua Liu, Jonathan Hurov, Katherine Yen, Sam Agresta, Eyal C. Attar, Susan Pandya, Patrick Y. Wen
201615
15
Pharmacokinetics, absorption, metabolism, and excretion of [14C]ivosidenib (AG-120) in healthy male subjects
Cancer Chemotherapy and Pharmacology ·Chandra Prakash, Bin Fan, Syed A. Altaf, Sam Agresta, Hua Liu, Hua Yang
201914
16
Abstract 3116: AG-221 offers a survival advantage in a primary human IDH2 mutant AML xenograft model
Cancer Research ·Kate Ellwood-Yen, Fang Wang, Jeremy Travins, Yue Chen, Hua Yang, Kim Straley, Sung Choe, Marion Dorsch, Sam Agresta, David P. Schenkein, Scott A. Biller, Michael Su
20146
17
Evaluation of Pharmacokinetic-Pharmacodynamic (PKPD) Relationship of an Oral, Selective, First-in-Class, Potent IDH2 Inhibitor, AG-221, from a Phase 1 Trial in Patients with Advanced IDH2 Mutant Positive Hematologic Malignancies
Blood ·Bin Fan, Yue Chen, Fang Wang, Katharine Yen, Luke Utley, Caroline Almon, Scott A. Biller, Sam Agresta, Hua Yang
20146
18
Evaluation of the Pharmacokinetics of AG-221, a Potent Mutant IDH2 Inhibitor, in Patients with IDH2-Mutation Positive Advanced Hematologic Malignancies in a Phase 1/2 Trial
Blood ·Yue Gao, Bin Fan, Kha Le, Erika Manyak, Hua Yang, Katherine Yen, Sam Agresta, Eyal C. Attar, Jian Chen, Qiang Xu, Alessandra Tosolini, Jay Mei, Anjan Thakurta, Robert Knight, Yan Li
20155
19
Abstract 1194: IDH1 mutant inhibitor induces cellular differentiation and offers a combination benefit with Ara-C in a primary human Idh1 mutant AML xenograft model
Cancer Research ·Kate Ellwood-Yen, Yue Chen, Fang Wang, René M. Lemieux, Janeta Popovici-Müller, Hua Yang, Kimberly Straley, Sung Choe, Marion Dorsch, Sam Agresta, David P. Schenkein, Scott A. Biller, Michael Su
20143
20
Abstract C90: HER2-targeted liposomal doxorubicin MM-302 has a favorable cardiosafety profile in preclinical models.
Molecular Cancer Therapeutics ·Elena Geretti, Joe Reynolds, Bart S. Hendriks, Isabelle Eckelhofer, Chris Espelin, Daniel F. Gaddy, Stephan G. Klinz, Helen Lee, Shannon C. Leonard, Ken Olivier, Sam Agresta, Clet Niyikiza, Ulrik B. Nielsen, Thomas J. Wickham
20113

About Sam Agresta

Sam Agresta is a scholar working on Hematology, Cancer Research, Molecular Biology, Oncology and Genetics, having authored 27 papers that have together received 912 indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (14 papers), Cancer Genomics and Diagnostics (8 papers), Cancer, Hypoxia, and Metabolism (8 papers), Epigenetics and DNA Methylation (5 papers), Erythrocyte Function and Pathophysiology (4 papers), Histone Deacetylase Inhibitors Research (4 papers), Multiple Myeloma Research and Treatments (3 papers) and Glioma Diagnosis and Treatment (3 papers). The work is most often cited by research in Hematology (442 citations), Genetics (285 citations), Cancer Research (315 citations), Molecular Biology (474 citations) and Oncology (121 citations). Sam Agresta has collaborated with scholars based in United States, France and Ireland. Frequent co-authors include Katharine Yen, Hua Yang, Camelia Gliser, Hagop M. Kantarjian, Courtney D. DiNardo, Bin Fan, Marina Konopleva, Sherry Pierce, Keyur P. Patel and Farhad Ravandi. Their work appears in journals such as Blood, Cancer Research, Molecular Cancer Therapeutics, Journal of Clinical Oncology and Investigational New Drugs.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ashwin KishtagariBreakdown of academic impact, for papers by Annette FasanBreakdown of academic impact, for papers by Zineb HamilouBreakdown of academic impact, for papers by Gabriella SammarelliBreakdown of academic impact, for papers by Dong‐ming YaoBreakdown of academic impact, for papers by Carrie BrownsteinBreakdown of academic impact, for papers by Kathy L. McGrawBreakdown of academic impact, for papers by Katherine WaghornBreakdown of academic impact, for papers by Camelia GliserBreakdown of academic impact, for papers by Marie Jarošová